Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer

KOSUKE HASHIMOTO, KYOICHI KAIRA, HISAO IMAI, YU MIURA, AYAKO SHIONO, ATSUTO MOURI, OU YAMAGUCHI, KUNIHIKO KOBAYASHI, HIROSHI KAGAMU and ICHIEI KUJI
Anticancer Research April 2024, 44 (4) 1541-1551; DOI: https://doi.org/10.21873/anticanres.16951
KOSUKE HASHIMOTO
1Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KYOICHI KAIRA
1Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kkaira1970@yahoo.co.jp
HISAO IMAI
1Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YU MIURA
1Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AYAKO SHIONO
1Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ATSUTO MOURI
1Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
OU YAMAGUCHI
1Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KUNIHIKO KOBAYASHI
1Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI KAGAMU
1Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ICHIEI KUJI
2Department of Nuclear Medicine, International Medical Center, Saitama Medical University, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Chemo-immunotherapy, including the programmed death ligand 1 (PD-L1) antibody, is an effective treatment for patients with extensive-stage small-cell lung cancer (ES-SCLC). However, no biomarker has been established for the prediction of chemo-immunotherapy. Therefore, we investigated the potential of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) as a predictive marker. Patients and Methods: Forty-six patients with ES-SCLC who received 18F-FDG-PET immediately before combined platinum-based chemotherapy with PD-L1 blockade as a first-line treatment were eligible, and the maximum standard uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) on 18F-FDG uptake were evaluated. Results: PD-L1 and tumor infiltrative lymphocytes (TILs) were immunohistochemically analyzed in 36 of the 46 patients. A high MTV was significantly associated with poor performance status and low albumin levels, and there was a significant association between low albumin and high TLG. Univariate analysis identified sex, Brinkman index, and MTV as significant predictors of progression-free survival (PFS), and sex, SUVmax, MTV, and TLG as significant factors of overall survival (OS). Multivariate analysis revealed that sex, Brinkman index, and MTV were independent prognostic factors for PFS, and sex, SUVmax, MTV, and TLG were significant predictors of OS. SUVmax was significantly higher in patients with positive PD-L1 expression than in those with negative expression but was not significantly different between positive and negative TILs. Moreover, the levels of MTV and TLG were not closely associated with the levels of PD-L1 and TILs. Conclusion: MTV or TLG metabolic tumor activity is suitable for the prediction of chemo-immunotherapy outcomes in patients with ES-SCLC.

Key Words:
  • 18F-FDG-PET
  • SCLC
  • immunotherapy
  • PD-L1
  • metabolic tumor volume
  • predictor
  • Received January 5, 2024.
  • Revision received January 30, 2024.
  • Accepted February 2, 2024.
  • Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 44 (4)
Anticancer Research
Vol. 44, Issue 4
April 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer
KOSUKE HASHIMOTO, KYOICHI KAIRA, HISAO IMAI, YU MIURA, AYAKO SHIONO, ATSUTO MOURI, OU YAMAGUCHI, KUNIHIKO KOBAYASHI, HIROSHI KAGAMU, ICHIEI KUJI
Anticancer Research Apr 2024, 44 (4) 1541-1551; DOI: 10.21873/anticanres.16951

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer
KOSUKE HASHIMOTO, KYOICHI KAIRA, HISAO IMAI, YU MIURA, AYAKO SHIONO, ATSUTO MOURI, OU YAMAGUCHI, KUNIHIKO KOBAYASHI, HIROSHI KAGAMU, ICHIEI KUJI
Anticancer Research Apr 2024, 44 (4) 1541-1551; DOI: 10.21873/anticanres.16951
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
  • Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study
  • Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series
Show more Clinical Studies

Similar Articles

Keywords

  • 18F-FDG-PET
  • SCLC
  • immunotherapy
  • PD-L1
  • metabolic tumor volume
  • predictor
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire